Mainz Biomed
Mainz
About Mainz Biomed
Mainz BioMed is a molecular genetic diagnostics company that develops market-ready molecular genetic diagnostic solutions for life-threatening conditions. The company's molecular genetic diagnostic tools focus on early cancer detection. It markets ColoAlert, a non-invasive home test for colorectal cancer combining DNA and fecal immunochemical analysis, commercially available across Europe and the UAE. The company is advancing its pipeline with PancAlert, a PCR-based stool test for early pancreatic cancer, and has initiated pivotal FDA registration studies for a next-generation colorectal test using proprietary mRNA biomarkers, AI algorithms, and FIT components.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Public
- Employees: 51 – 100
- Estimated revenue: Less than $1M
- Total funding: $95.5M
- Funding stage: IPO
- Last round: Post-IPO Equity (Feb 2026)
- Ticker: nasdaq:MYNZ
- Website: mainzbiomed.com
- Phone: +49 (0) 6131 / 55428-60
Industries & Categories
Biotechnology, Genetics, Health Diagnostics, Medical
Social Profiles
Canonical: https://fsome.com/organization/mainz-biomed-16518 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.